Ulcerative Colitis Market to Expand on New Drug Pipeline

U.S. Accounts for 1.5 Million Diagnosed Cases in 2024

The market for ulcerative colitis (UC) therapies is poised for major growth, with the United States leading the expansion. In 2024, the U.S. recorded approximately 1.5 million diagnosed prevalent cases, representing nearly half of the total cases across the seven major markets (US, EU4, UK, and Japan). This rising prevalence, combined with better diagnostic technologies, is a primary driver of market growth.

Biopharmaceutical products remained the cornerstone of UC treatment in 2024, capturing the dominant market share. Advanced biologics like anti-TNF agents and newer targeted therapies have become standard for moderate-to-severe UC, fueling revenue growth as their adoption widens.

New Drug Pipeline Signals Treatment Shift

The therapeutic landscape is set to evolve further with several emerging therapies in late-stage development. Key drugs expected to launch by 2034 include obefazimod (Abivax), tulisokibart (Merck), Afimkibart (Roche), and MORF-057 (Eli Lilly). These next-generation treatments, including oral JAK inhibitors and S1P receptor modulators, offer improved efficacy and convenience, accelerating a shift away from older treatment algorithms.

Recent approvals have already broadened the landscape, with drugs like TREMFYA (Johnson & Johnson), SKYRIZI (AbbVie), VELSIPITY (Pfizer), and OMVOH (Eli Lilly) providing new targeted options. Despite this progress, a significant unmet need remains for safer and more effective long-term solutions.

Abivax and Merck Advance Late-Stage Clinical Trials

Key pharmaceutical developers are making significant progress in their clinical programs. In July 2025, Abivax announced positive results from its Phase III 8-week induction trials for obefazimod, its oral miR-124 enhancer. The company followed up in November 2025 with data showing the drug significantly improved the quality of life for patients with moderate-to-severe UC.

Merck is also advancing tulisokibart, a monoclonal antibody targeting TL1A, which it acquired through its purchase of Prometheus Biosciences. The therapy, currently in Phase III development, demonstrated superior efficacy over placebo for achieving clinical remission in a Phase II study for moderately to severely active ulcerative colitis.